A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance - Quiz - MDSpire

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.

  • By

  • Kimberly Noonan

  • Kevin Brigle

  • Charise Gleason

  • Carrie Bellerive

  • Mary Steinbach

  • Deborah Doss

  • March 4, 2026

  • 17 min

Share

Original Source(s)

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

  • by Kimberly Noonan, Kevin Brigle, Charise Gleason, Carrie Bellerive, Mary Steinbach, Deborah Doss

  • March 4, 2026

Related Content

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

  • February 26, 2025

  • 1 min
This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Biochemical Tumor Markers: Are New Testing Guidelines Fit for Purpose?

CLSI guidance achieves technical excellence but has some questionable omissions, says Mustafa Barbhuiya